Company Profile
——
Guangzhou Sinogen Pharmaceutical Co., Ltd. is a biotechnology company committed to the development and production of innovative biological oncology drugs to meet the global demand for the treatment of a broad malignant tumors.
Since its establishment in 2016, under the leadership of Dr. Allan Zhao and other three nationally distinguished experts, and through the joint efforts of dozens of researchers, the company has gradually established the world's first rapid broad-spectrum oncolytic bacteria technology platform, and completed the preclinical study, the development of CMC manufacturing process, and the construction of GMP-compliant large-scale production facilities of the core product, an oncolytic bacteria, named as SalMet-Vec . Our first-in-class product SalMet-Vec has obtained the IND approvals from US FDA , Taiwan FDA and China NMPA, and has launched international multi-center phase I/IIa clinical trials for a variety of malignant solid tumors in the United States, Taiwan region and mainland China.
Honor
——
Milestones
——
Chairman's Speech
——
Thank you for visiting us! Sinogen is entering a new era of prosperous development!
In 2017, China's official announcement to join the International Council for Harmonisation (ICH) has enabled the country to rapidly transit from a generic drugs-dominated industry over the past decades to a new era aimed at developing global innovative medicines. Sinogen will seize such a rare opportunity and rise to the challenge with full confidence.
Sinogen was founded in 2016 by four nationally distinguished experts returning from the United States. They are biomedical experts with an international perspective and rich experiences in drug research and development, manufacturing quality control, regulatory affairs, and clinical trials. Since its establishment, the company has always persistently advocated for the spirit of innovation, committed itself to the research and development of innovative medicine with global intellectual property rights, and set the goal of breakthrough progress in the treatment of many difficult-to-treat cancers.
We have always promoted the concept of people-oriented working environment, continuous innovation, integrity, cooperation and sharing, and aspiring to be the leading pharmaceutical enterprise in China. We always look for and welcome ambitious people sharing our development philosophy to join hands with us in creating a brilliant future of Sinogen!
Leadership
Team
——
July 2016
Established in Guangzhou as a R&D biopharmaceutical company in July 2016
August 2017
Obtained angel funding in August 2017
March 2020
Completed pre-series A funding in March 2020
September 2020
Completed series A funding in September 2020
October 2020
SalMet-Vec received IND approval (Intravenous Injection) from the US FDA in October 2020
March 2021
SalMet-Vec received IND approval (Intratumoral Injection) from the US FDA in March 2021
November and December 2022
SalMet-Vec obtained FDA Orphan Drug Designation for osteosarcoma and hepatocellular carcinoma in November and December 2022
August 2023
SalMet-Vec obtained FDA Orphan Drug Designation for small-cell lung carcinoma in August 2023
September 2023
SalMet-Vec received IND approval (intravenous injection and intratumoral injection) from China NMPD in September 2023
December 2023
Completed series B funding in December 2023
January 2024
SalMet-Vec obtained FDA Fast Track Certification for osteosarcoma in January 2024
®
®
®
®
April 2024
Started to expand Phase II clinical trials in China, and completed the first trial enrollment administration in Phase II clinical trials in April 2024
May 2024
SalMet-Vec obtained FDA Fast Track Certification for squamous cell carcinoma of the head and neck in May 2024
®
May 2022
Completed pre-series B funding in May 2022
February 2023
SalMet-Vec completed the first trial enrollment administration in Phase I clinical trials in the United States in February 2023
®
®
®
®
®
Guangzhou Sinogen Pharmaceutical Co.,Ltd.all rights reserved 粤ICP备20063851号
Address:Room 101, 1st Floor, Building C5, Science and Technology Enterprise Accelerator, Huangpu District, Guangzhou Email : sinogen@sinogen.cc Service Time : Work days 9:00 ~ 17:00
Science&Prouduct
Contact Us
sinogen@sinogen.cc
Work days 9: 00 ~17: 00
Address:Room 101, 1st Floor, Building C5,
Science and Technology Enterprise Accelerator,
Huangpu District, Guangzhou
Investor Relations
Careers